Daniel de Boer describes how Axiomer harnesses the body's natural ADAR editing process to turn an A into an I, he covers NHP data for...

Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...

Founder & CEO Tao Fu walks us through the company's ATTOBODY platform and discusses programs targeting IL31 and IL31 x IL13.

Jason Cole describes how Gene Coding can deliver large sequences to the genome without viral vectors or RNA guides, and describes how...

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a...

Dr. Jhoti discusses the history of Astex, shows us a state-of-the-art cryo-EM microscope they have on site, and highlights the three...

Kevin Lee shows us what a bicycle looks like and compares and contrasts them to traditional antibodies.

Lindy Durrant describes Scancell's DNA and peptide based vaccine programs, as well as early stage antibody work.

Dave Hallett gives an overview of Exscientia and describes how important testing compounds in the company's labs has been to its...

Lian Ni Lee and Susannah de Jager discuss how quickly Infinitopes has been able to get ready for the clinic.

She describes OMass' platform and rare disease focus.

LabGenius is combining in silico design and automation to optimize antibody design, oftentimes with a non-obvious result.

In a wide ranging interview, Emma Walmsley discusses GSK's R&D activities in its four main areas of focus.

Kristen Albright describes Prokarium's bladder cancer program, which went into the clinic earlier this year, and a platform (including a...

Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.

He explains the decision to withdraw e-therapeutics from London AIM and describes the HepNet and GalOmic platforms that have produced the...

He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.

Jing Wang explains how her company is focused on restoring CNS conditions such as MS and ALS, and talks targets.

Chris Bahl walks through the attributes of miniproteins.

Francisco LePort and Martin Borch Jensen describe the science behind the mosiac screening process.